Why the study?
Does apixaban resolve left ventricular thrombus in a patient with hypertrophic cardiomyopathy and atrial fibrillation?
Does apixaban resolve left ventricular thrombus in a patient with hypertrophic cardiomyopathy and atrial fibrillation?
This case report provides initial evidence that apixaban may be effective in resolving left ventricular thrombus in patients with hypertrophic cardiomyopathy.
Hypothesis-generating for apixaban in LV thrombus with HCM and AF; prospective trials needed before clinical adoption.
Anticoagulation with warfarin is the main treatment of intracardiac thrombus. While novel oral anticoagulants (NOACs) have been approved by the US Food and Drug Administration (FDA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF), they are not indicated for resolution of intracardiac thrombus. The case of a 60-year-old woman with left ventricular (LV) thrombus secondary to hypertrophic cardiomyopathy and AF is described in the present report. Indications for oral anticoagulation were AF and LV thrombus. Thrombus was dissolved after 1 month of apixaban treatment. To the best of our knowledge, this is the first report that describes the resolution of LV thrombus with apixaban treatment in a patient with hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
A 2016 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: